The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
Open accessAbstract
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by autoantibodies targeting neuromuscular junction proteins. In the majority of patients (~85%) antibodies against the muscle acetylcholine receptor (AChR) are detected, while in 6% antibodies against the muscle-specific kinase (MuSK) are detected. In ~10% of MG patients no autoantibodies can be found with the classical diagnostics for AChR and MuSK antibodies (seronegative MG, SN-MG), making the improvement of methods for the detection of known autoantibodies or the discovery of novel antigenic targets imperative. Over the past years, using cell-based assays or improved highly sensitive immunoprecipitation assays, it has been possible to detect autoantibodies in previously SN-MG patients, including the identification of the low-density lipoprotein receptor-related protein 4 (LRP4) as a third MG autoantigen, as well as AChR and MuSK antibodies undetectable by conventional methods. Furthermore, antibodies against other extracellular or intracellular targets, such as titin, the ryanodine receptor, agrin, collagen Q, Kv1.4 potassium channels and cortactin have been found in some MG patients, which can be useful biomarkers. In addition to the improvement of diagnosis, the identification of the patients’ autoantibody specificity is important for their stratification into respective subgroups, which can differ in terms of clinical manifestations, prognosis and most importantly their response to therapies. The knowledge of the autoantibody profile of MG patients would allow for a therapeutic strategy tailored to their MG subgroup. This is becoming especially relevant as there is increasing progress towards the development of antigen-specific therapies, targeting only the specific autoantibodies or immune cells involved in the autoimmune response, such as antigen-specific immunoadsorption, which have shown promising results. We will herein review the advances made by us and others towards development of more sensitive detection methods and the identification of new antibody targets in MG, and discuss their significance in MG diagnosis and therapy. Overall, the development of novel autoantibody assays is aiding in the more accurate diagnosis and classification of MG patients, supporting the development of advanced therapeutics and ultimately the improvement of disease management and patient quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
Induction, assembly, maturation and maintenance of a postsynaptic apparatus
Sanes, J. R., & Lichtman, J. W. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097557 · Cited by 1,025
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Self-citationAn adaptive coding model of neural function in prefrontal cortex
Duncan, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097575 · Cited by 874
A systematic review of population based epidemiological studies in Myasthenia Gravis
Carr, A. S., Cardwell, C. R., McCarron, P. O., & McConville, J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-46 · Cited by 756
An adaptive coding model of neural function in prefrontal cortex
Duncan, J. (2001) · UCL Discovery (University College London) · Cited by 738
Bang, M.-L., Centner, T., Fornoff, F., Geach, A. J., Gotthardt, M., McNabb, M., Witt, C. C., Labeit, D., Gregorio, C. C., Granzier, H., et al. (2001) · Circulation Research · doi:10.1161/hh2301.100981 · Cited by 712
Lrp4 is a receptor for Agrin and forms a complex with MuSK
Kim, N., Stiegler, A. L., Cameron, T. O., Hallock, P. T., Gomez, A. M., Huang, J. H., Hubbard, S. R., Dustin, M. L., & Burden, S. J. (2008) · Cell · doi:10.1016/j.cell.2008.10.002 · Cited by 676
Gautam, M., Noakes, P. G., Mudd, J., Nichol, M., Chu, G. C., Sanes, J. R., & Merlie, J. P. (1995) · Nature · doi:10.1038/377232a0 · Cited by 545
Cited by
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Metadata
- Authors
- Lazaridis, K., & Tzartos, S. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-14
- Volume
- 11
- Pages
- 212-212
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3006331137
- Cited by
- 287
- References
- 77
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. https://app.cochat.ai/papers/10.3389/fimmu.2020.00212
- The paper
- Lazaridis, K., & Tzartos, S. J. (2020). Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.